STARTVAC^® against Staphylococcus aureus

Bi, Y.; Wang, YJ.; Qin, Y.; Guix Vallverdú, R.; Maldonado García, J.; Sun, W., et al. (2016)

The objectives of this study were to estimate the herd prevalence ofmajor mastitis pathogens in bulk tank milk (BTM) in China dairy herds, to etermine the relationship between the presence of mastitis pathogens and bulk tank milk somatic cell counts (BTSCC), and to investigate the impact of different dairy cattle farming modes and region on bacterial species. BTM samples collected from 894 dairy herds in China were examined for the presence of mastitis pathogens.

Gelasakis, A. I.; Mavrogianni, V. S.; Petridis, I. G.; Vasileiou, N. G. C.; Fthenakis, G. C.

Bacterial mastitis is a significant welfare and financial problem in sheep flocks. This paper reviews the recently published literature, including publications that highlight the significance and virulence factors of the causal agents, especially Staphylococcus aureus and Mannheimia haemolytica, the primary causes of the disease.

Azevedo, C.; Pacheco, D.; Soares, L.; Romão, R.; Moitoso, M.; Maldonado, J.; Guix, R.; Simões, J.; Trop Anim Health Prod., 2016.

This study aimed to assess the degree of contamination of bulk tank milk (BTM) by Staphylococcus spp. and coliform bacteria and to identify major milking practices that help perpetuate them in dairy cattle herds in São Miguel Island .

Plewik, M.; Jażdż-Maszkowska, M.; Weterynariaw Terenie, 2016 (this article is available in Polish)

A modern approach to mastitis management; implementation of complex milk quality control program on dairy farm with Staphyloccocus aureus infected cows.

Prenafeta, A.; Sitjà, M.; Holmes, M.A.; Paterson, G.K.; Journal of Dairy Science, Vol. 97, Issue 8, p4838–4841.

Bardiaua, M.; Caplinb, J; Detilleuxc, J.; Graberd, H.; Moronie, P.; Taminiaug, B.; Mainila, J.G.; Veterinary Microbiology, 2016.

The first perspective of this study would be to check for the presence of these genes in a larger collection of strains to assess of their specificity for each cluster. In addition, it would be beneficial to study these features (intracellular survival, biofilm formation, capsular typing and agr-typing) in S. aureus strains isolated from other hosts and other pathologies to specify if these clusters are specific to bovine mastitis S. aureus strains or are present in all S. aureus strains.

Schukken, Y.; Journal of Dairy Sci. 97:1–15, 2014.

A large field study (40,000 samples) concludes that vaccination was a valuable tool in reducing incidence and prevalence of staphylococcal infections and is able to reduce to half the basic reproduction ratio.

Piepers, S.; NMC, 2014.

A discussion on the cause and effects of bovine mastitis along with an explanation of what a vaccine is, the efficacy and effectiveness of a vaccine and details of vaccines against mastitis with results of their effectiveness.

Schukken, Y.; NMC, 2014.

This article discusses immune response, with a distinction between after intramammary infections in lactaction and after intramammary infection in late gestation.

Prenafeta, A.; NMC, 2014.

An explanation of bio-film and its implications in ruminant mastitis caused by S. aureus with details of vaccines against the bio-film of S. aureus to combat mastitis in ruminants.

Petzer, I.; The Dairy Mail, 2014.

After two years of testing, a mastitis vaccine has been registered in South African. This article discusses the principles on which this vaccine works and provides findings such as an increased milk production and decreased SCC.

Biggs, A.; NMC, 2014.

Clinical mastitis reduced by 54%, S. aureus reduced by 71% and first infections reduced by 49%.

Torres, E.; NMC, 2014.

Evaluate the effectiveness of two different vaccination protocols against bovine mastitis during lactation (STARTVAC^®, HIPRA).

Guccine, J.; NMC, 2014.

Two different clinical trials based on STARTVAC^® vaccine use were evaluated for the first time in dairy Mediterranean Buffalo.

Piepers, S.; Buistrissima 2013.

Lower incidence of S.aureus and reduction of the duration of infection (preliminary results). After a challenge there was no decrease of the milk produccion in vaccined cows and the level of antibodies Anti-SAAC and Anti-J5  in milk and blood were higher.

Ortega, R.; STARTVAC^® Library 2013.

Milking routine, teat end condition.

Theron, L.; STARTVAC^® Library 2013.

Epidemiological approach to mastitis at herd level.

Biggs, A.; BMC 2013.

Reduction of clinical mastitis, S. aureus prevalence and first infections, Increase of the percentage of healthy animals.

Kromker, V.; STARTVAC^® Library 2013.

Management of S. aureus mastitis at herd level.

Ortega, R.; NMC 2013.

Increase of cure rate after dry-off with vaccination classic protocol, decrease of S. aureus prevalence 30% to 1,26%, BTSCC decrease and reduction in treatment costs in 50%.

Tacken, G.; NMC 2013.

Results were much less cases of acute severe mastitis, SCC reduction, culling rate reduction and reduction of mortalility, reduction in milk losses and treatment costs.

Coomans, D.; NMC 2013.

Increase of animals with SCC < 200,000, decrease of clinical mastitis rate, decrease of culling rate, reduction of the cost of mastitis antibiotics and increase of milk production per cow per year.

Lindsay, C.; NMC 2013.

Reduction of SCC herd average, reduction of culling rate and clinical mastitis, reduction of duration of extended therapy , decrease of new infections and repeated cases.

Drysdale, R.; NMC 2013.

Reduction of BTSCC, reduction of culling rate, reduction of clinical mastitis, increase of healthy animals < 200.000 cells/ml.

Nikolayevich, G. V.; WBC 2012.

Reduction in clinical mastitis (6% to 2%), reduction in animal losses 3-5 to 1 per month, clearance of isolates of S. aureus, less use of antibiotics (reduction in 55-60%), increase in cure rate and BTSCC 257.000 to 163.000.

Sousa, J.; WBC 2012.

Reduction in BTSCC, S. aureus prevalence 19%to 3%, less systemic antibiotic treatments 24 to 10, less clinical mastitis cases 92 to 77.

Piepers, S.; WBC 2012.

Vaccinated cows less severe inflamatory response, more milk production, antibodies anti-S. aureus and anti-E. coli.in serum and in milk.

Piepers, S.; WBC 2012.

Vaccinated cows less severe inflamatory response, more milk production, antibodies anti-S. aureus and anti-E. coli in serum and in milk.

Menezes, A.; WBC 2012.

Positive bulk milk samples for S. aureus, E. coli and coliforms are correlated with high BTSCC.

Jimenez, L. M.; WBC 2012.

Redution of E. coli infections in 17%, reduction of clinical mastitis in 65% ,reduction of new infection rate 8,8% vs 11,8% and clearance of S. aureus isolates in vaccinated vs 3% in non vaccinated.

Chaffer, M.; STARTVAC^® Library 2012.

Inmunity and mastitis, is it possible to vaccinate?

Prenafeta, A.; STARTVAC^® Library 2012.

General aspects of biofilm and its implications in ruminant mastitis.

Schukken, Y.; WBC 2012.

Efficacy in reduce new infections 57% and in reduce duration of infection 70%, about 30 days less of infection period in vaccinated animals.

Pinho, L.; WBC 2012.

Decrease of S. aureus prevalence, lower BTSCC, and individual SCC.

Wernitznig, M. J.; WBC 2012.

Increase the number of animals SCC < 100.000, reduce the number of animals with S. aureus infection and decrease BTCC.

Geninatti, G.; WBC 2012.

Reduction in BTSCC 650.000 to 250.000, clearance of S. aureus isolates after vaccination.

Bronzo, V.; WBC 2012.

Biofilm is a S. aureus virulent factor involved in chronocity of bovine mastitis.

Wernitznig, M. J.; EBF 2011.

No new infections caused by S. auerus after vaccination, healthy cows SCC < 100.000 increased in 45%, heifers free of mastitis.

Ortega, R.; EBF 2011.

Less clinical mastitis 20% to 5%, reduction of mastitis causing pathogens prevalence E. coli 33,35 to 7,8%, S. aureus 11,7% to 2%, reduction of SCC 600.000 to 283.000 and increase of healthy cows 45% to 60%.

Hofer, J.; EBF 2011.

Reduction in S. aureus isolates from 58 to low level, decrease in individual SCC and BTSCC.

Navarro, C.; EBF 2011.

Reduction of clinical mastitis 12 to 2%, S. aureus prevalence decrease 41% to 6%, reduction of BTSCC 566.000 to 233.000, reduction of chronic cows 12% to 2%, increase of healthy cows 44 to 73%.

Schmitt. E., SNGTV 2011.

Reduction in mastitis rate 136 to 55% and in SCC 308.000 to 227.000.

Schmitt. E., STARTVAC Library 2011.

Reduction in mastitis rate 136 to 55% and in SCC 308.000 to 227.000.

Jimenez, L. M.; NMC 2010.

Reduction of new infection rate 8 vs 16 in cows and 6,2% vs 24,1% in primiparous, reduction of S. aureus isolates, increase of number of E. coli isolates, reduction in clincial mastitis 30% vs 43,2% in cows and 3,4% vs 13,3% in primiparous.

Serieys, F.; SNGTV 2010.

Reduction of more than 25%somatic cell counts in multiparous cows, i.e. approximately 100,000 fewer cells/ml (P<0.05), and in nearly 30% fewer antibiotic treatments during lactation (P<0.05).

March, R.; NMC 2010.

Less clinical and subclinical mastitis, less severity in clinical mastitis (SCC, milk aspect, mamary gland aspect, mastitis treatments).